AUTHOR=Lahiri Durjoy , Seixas-Lima Bruna , Roncero Carlos , Verhoeff Nicolaas Paul , Freedman Morris , Al-Shamaa Sarmad , Chertkow Howard 

TITLE=CAPS: a simple clinical tool for β-amyloid positivity prediction in clinical Alzheimer syndrome

JOURNAL=Frontiers in Neurology

VOLUME=Volume 15 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1422681

DOI=10.3389/fneur.2024.1422681

ISSN=1664-2295

ABSTRACT=With the advent of anti-β-amyloid therapies, clinical distinction between Aβ+ and Aβ-in cognitive impairment is becoming increasingly important for stratifying referral and better utilization of biomarker assays. METHODS: Cognitive profile, rate of decline, neuropsychiatric inventory questionnaire (NPI-Q) and imaging characteristics were collected from 52 subjects with possible/ probable AD. RESULTS: Participants with Aβ+ status had lower baseline MMSE scores (24.50 vs 26.85, p=0.009) and higher total NPI-Q scores (2.73 vs 1.18, p<.001). NPI-Q score was found to be the only independent predictor for β-amyloid positivity (p=.008). A simple scoring system, namely CAPS, was developed by using the following parameters: NPI-Q, rapidity of cognitive decline, and white matter microangiopathy. Data from 48 participants were included in the analysis of accuracy of CAPS. CAP Score of 3 or 4 successfully classified Aβ+ individuals in 86.7% cases. DISCUSSION: CAPS is a simple clinical tool for use in primary care and memory clinic settings to predict β-amyloid positivity in individuals with clinical Alzheimer Syndrome can potentially facilitate referral for Anti Aβ therapies.